Adage Capital Partners Gp, L.L.C. Liquidia Corp Transaction History

Adage Capital Partners Gp, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.27 - $8.15 $4.24 Million - $5.51 Million	-675,522 Reduced 84.44%	124,478 $789,000
Q2 2023 Aug 14, 2023	BUY	$6.63 - $9.9 $611,465 - $913,047	92,227 Added 13.03%	800,000 $6.28 Million
Q4 2022 Feb 14, 2023	SELL	$4.68 - $6.54 $431,622 - $603,164	-92,227 Reduced 11.53%	707,773 $4.51 Million
Q3 2022 Nov 14, 2022	SELL	$3.73 - $8.39 $373,000 - $839,000	-100,000 Reduced 11.11%	800,000 $4.35 Million
Q2 2022 Aug 15, 2022	BUY	$3.37 - $7.55 $3.03 Million - $6.8 Million	900,000 New	900,000 $3.92 Million

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.